CMV-GFP scAAV (Serotype BR1)

CMV-GFP scAAV (serotype BR1) represents a unique class of adeno-associated virus (AAV) vectors. These vectors are a cornerstone of gene therapy research because they can efficiently deliver genetic material into cells without integrating into the host genome, thereby minimizing the risk of insertional mutagenesis. The CMV promoter, widely recognized for its strong constitutive expression, drives the expression of green fluorescent protein (GFP) within this vector. GFP serves as a molecular marker, allowing researchers to visualize and track transgene expression in living cells and organisms.

The single-stranded AAV (scAAV) used here is able to self-complement to form a stable duplex, hence the name "self-complementary," allowing for more rapid gene expression. This property makes scAAV vectors particularly useful for therapeutic applications that require a robust and immediate gene expression response. Serotype BR1 AAV has been genetically engineered to have enhanced infectivity and specificity, expanding its potential to target multiple tissue types. This serotype is part of a growing toolkit for precision in vivo gene delivery that is expanding the promise of fields such as medical research, developmental biology, and genetic engineering.